Announcements Trials
Browse Landscape

Phase

Phase 1/2 3Phase 2/3 2Phase 3 1Phase 2 1

Status

Recruiting 2Active not recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 2

Conditions

Platinum-resistant Ovarian Cancer 1Ovarian Cancer Recurrent 1Adenoviridae Infections 1

Interventions

pembrolizumab 86Cyclophosphamide 58Carboplatin 57Specimen Handling 55fludarabine 46Nivolumab 44Magnetic Resonance Spectroscopy 44Gemcitabine 41Biopsy 40Bevacizumab 36Dexamethasone 32venetoclax 31Paclitaxel 29Cisplatin 29Pemetrexed 28Injections 28Docetaxel 26atezolizumab 22Ipilimumab 22Capecitabine 22Temozolomide 21Rituximab 20Oxaliplatin 20Cetuximab 20Azacitidine 20Lenalidomide 19Fulvestrant 19abemaciclib 18Fluorouracil 17Vincristine 16

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × 1-dodecylpyridoxal × 90 days × Clear all
NCT06843447 2026-05-26

MK-5909-003

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting
460 enrolled
Gynecologic

Ovarian Cancer Recurrent

NCT05271318 2026-05-05

PROTA

TILT Biotherapeutics Ltd.

Phase 1/2 Active not recruiting
29 enrolled

Adenoviridae Infections

NCT05551507 2026-05-04

IN10018 in Combination With Standard Chemotherapy in High-grade Serous Epithelial Ovarian Cancer

InxMed (Shanghai) Co., Ltd.

Phase 1/2 Recruiting
150 enrolled
Gynecologic

Platinum-resistant Ovarian Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡